The role of tau phosphorylation and cleavage in neuronal cell death
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
The microtubule-associated protein tau is the primary component of the intracellular filamentous deposits found in Alzheimer's disease (AD) brain and also in a family of neurodegenerative diseases called 'tauopathies', where tau pathology is the primary, defining characteristic with little or no amyloid-beta (Abeta) pathology. It has been demonstrated that tau modifications such as hyperphosphorylation and truncation might be important events in the process leading to tau intracellular aggregation and neuronal cell death. The discovery of tau gene mutations in frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) reinforced the predominant role attributed to tau proteins in the pathogenesis of neurodegenerative disorders. This review highlights recent findings concerning the normal metabolism and function of tau, as well as the abnormal processing and function of tau in AD and in the tauopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 1×
“A dysfunction of the UPS has been proposed in numerous neurological disorders such as AD, Huntington’s disease, Parkinson’s disease, and Angelman’s syndrome (254-259).”
BackgroundGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 12×
“Although the role of NFTs as a toxic mediator in neuronal dysfunction and death in AD is still not clear, the tau aggregation is closely related with the pathology of AD (203), and there is increasing data to suggest that a conformational change in tau that precedes the formation of PHFs and NFTs may be the toxic enti…”
BackgroundInfluentialGSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · cited 18×
“However, GSK3beta phosphorylates and regulates numerous other proteins (131), and therefore the possibility remains that GSK3beta indirectly regulates tau phosphorylation in vivo.”
InfluentialCaughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · cited 2×
“Although the role of NFTs as a toxic mediator in neuronal dysfunction and death in AD is still not clear, the tau aggregation is closely related with the pathology of AD (203), and there is increasing data to suggest that a conformational change in tau that precedes the formation of PHFs and NFTs may be the toxic enti…”
BackgroundA multiubiquitin chain is confined to specific lysine in a targeted short-lived protein
Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D. J., Gonda, D. K., & Varshavsky, A. (1989) · Science · doi:10.1126/science.2538923 · Cited by 1,535 · cited 1×
“In addition, most PHFtau is mono-ubiquitylated (247), which is not a signal for ubiquitin-mediated degradation (249, 250).”
BackgroundMutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474 · cited 3×
“These diseases include the FTDP-17 cases, which are caused by mutations in the tau gene (11-13).”
BackgroundA68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 1×
“Although tau in AD and other tauopathies is present predominantly as an intact full-length molecule (212-216), tau in AD NFTs has been shown to be truncated both at Glu391 and Asp421 (47, 217).”
BackgroundTau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321 · cited 1×
“Furthermore, treatment of cells with lithium, a selective inhibitor of GSK3, significantly attenuates tau phosphorylation (126-128).”
BackgroundGoedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E., & Klug, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.4051 · Cited by 1,134
Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease
KIDD, M. (1963) · Nature · doi:10.1038/197192b0 · Cited by 1,012 · cited 1×
“In AD, tau filaments consist primarily of PHFs, with straight filaments being a minority species (48, 177, 178).”
BackgroundGoedert, M., & Jakes, R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07870.x · Cited by 929 · cited 3×
“In adult human brain, the ratio of 3R tau to 4R tau isoforms is about one and the 1N, 0N, and 2N isoforms comprise about 54%, 37%, and 9%, respectively, of total tau (28).”
BackgroundDrewes, G., Ebneth, A., Preuss, U., Mandelkow, E.-M., & Mandelkow, E. (1997) · Cell · doi:10.1016/s0092-8674(00)80208-1 · Cited by 878
Impaired Proteasome Function in Alzheimer's Disease
Keller, J. N., Hanni, K. B., & Markesbery, W. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750436.x · Cited by 848 · cited 1×
“A dysfunction of the UPS in AD brains has been suggested, given the data that proteasome activity is decreased in AD brains (260) and that PHF-tau extracted from AD brains has been shown to be able to inhibit the proteasome in vitro (261).”
BackgroundEbneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., Mandelkow, E.-M., & Mandelkow, E. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.3.777 · Cited by 820
Bancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., & Wisniewski, H. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91396-6 · Cited by 818
Tau is essential to β-amyloid-induced neurotoxicity
Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., & Ferreira, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092136199 · Cited by 807
Biernat, J., Gustke, N., Drewes, G., Mandelkow, E., & Mandelkow, E. (1993) · Neuron · doi:10.1016/0896-6273(93)90279-z · Cited by 796
O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease
Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775 · cited 1×
“It has also been reported that hyperphosphorylated tau proteins in AD brain are N-glycosylated (in contrast to O-glycosylation) and that glycan(s) may maintain the helicity of PHF or facilitate the subsequent abnormal hyperphosphorylation of tau in AD brain (206, 276, 277).”
BackgroundCHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation
Petrucelli, L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh083 · Cited by 723
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms
Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y., Duff, K., & Davies, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01879.x · Cited by 722
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 1×
“treatment also decreases tau phosphorylation in mouse models in which mutant FTDP-17 tau is overexpressed (129, 130).”
BackgroundDomains of tau Protein and Interactions with Microtubules
Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E.-M., & Mandelkow, E. (1994) · Biochemistry · doi:10.1021/bi00198a017 · Cited by 655 · cited 4×
“The proline-rich domain and pseudorepeat C-terminal domain R’, which are upstream and downstream of the repeats, respectively, strongly enhance the tau’s microtubule binding affinity (17, 19).”
BackgroundInfluentialTau phosphorylation in neuronal cell function and dysfunction
Johnson, G. V. W., & Stoothoff, W. H. (2004) · Journal of Cell Science · doi:10.1242/jcs.01558 · Cited by 624
Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons
Chen, J., Kanai, Y., Cowan, N. J., & Hirokawa, N. (1992) · Nature · doi:10.1038/360674a0 · Cited by 601
Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E., & Mandelkow, E.-M. (1999) · Biochemistry · doi:10.1021/bi981874p · Cited by 564
Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M. K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Neuron · doi:10.1016/s0896-6273(00)81127-7 · Cited by 564 · cited 4×
“In addition, overexpression of the shortest human tau isoform significantly inhibits fast axonal transport in ventral root axons (95).”
BackgroundInfluentialTau protein binds to microtubules through a flexible array of distributed weak sites.
Butner, K. A., & Kirschner, M. W. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.3.717 · Cited by 550
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology
Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., LaFerla, F. M., Rohn, T. T., & Cotman, C. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420640 · Cited by 543 · cited 3×
“It has been suggested that truncated tau, albeit not a large amount, may play a significant role in the neuronal cell death and PHF formation given that truncated tau at Asp421 (due to caspase-cleavage) have been shown to be associated with apoptosis in cultured cells (218, 219), and that truncated tau at Glu391 was s…”
BackgroundPhosphoprotein Phosphatase Activities in Alzheimer Disease Brain
Gong, C., Singh, T. J., Grundke‐Iqbal, I., & Iqbal, K. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03603.x · Cited by 527 · cited 2×
“In particular, the activities of PP2A and PP1 are reduced by ~20-30% in AD brain (168, 172).”
BackgroundInhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice
Dawson, H. N., Ferreira, A., Eyster, M. V., Ghoshal, N., Binder, L. I., & Vitek, M. P. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.6.1179 · Cited by 527
The microtubule binding domain of tau protein
Lee, G., Neve, R. L., & Kosik, K. S. (1989) · Neuron · doi:10.1016/0896-6273(89)90050-0 · Cited by 500 · cited 1×
“These three- or four-repeat domains contain imperfect 18-amino acid repeats separated by 13- or 14amino acid-long inter-repeat sequences (20).”
BackgroundProteasome inhibition by paired helical filament‐tau in brains of patients with Alzheimer's disease
Keck, S., Nitsch, R., Grune, T., & Ullrich, O. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01642.x · Cited by 483
Pei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199909000-00011 · Cited by 459
Frontotemporal Dementia and Corticobasal Degeneration in a Family with a P301S Mutation in Tau
Bugiani, O., Murrell, J. R., Giaccone, G., Hasegawa, M., Ghigo, G., Tabaton, M., Morbin, M., Primavera, A., Carella, F., Solaro, C., et al. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199906000-00011 · Cited by 450
Goode, B., & Feinstein, S. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.5.769 · Cited by 399
Novak, M., Kabat, J., & Wischik, C. M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05665.x · Cited by 398 · cited 1×
“It has been suggested that truncated tau, albeit not a large amount, may play a significant role in the neuronal cell death and PHF formation given that truncated tau at Asp421 (due to caspase-cleavage) have been shown to be associated with apoptosis in cultured cells (218, 219), and that truncated tau at Glu391 was s…”
BackgroundMicrotubule-associated Protein/Microtubule Affinity-regulating Kinase (p110mark)
Meyer, H. E., Mandelkow, E.-M., Drewes, G., Trinczek, B., Illenberger, S., Biernat, J., Schmitt-Ulms, G., & Mandelkow, E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7679 · Cited by 388 · cited 2×
“MARK selectively phosphorylates a KXGS motif, which is present in each microtubule binding repeat of tau, as well as other microtubule-associated proteins (57, 148).”
BackgroundGoedert, M., Jakes, R., Crowther, R. A., Cohen, P., Vanmechelen, E., Vandermeeren, M., & Cras, P. (1994) · Biochemical Journal · doi:10.1042/bj3010871 · Cited by 375 · cited 8×
“Furthermore, when cell lysates were separated into soluble cytosolic and insoluble cytoskeletal fractions, almost all the tau phosphorylated at the Thr231 epitope was present in the soluble fraction (64, 65).”
BackgroundInfluentialThe Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine
Arnold, C. S., Johnson, G. W., Cole, R. N., Dong, D. L.-Y., Lee, M., & Hart, G. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28741 · Cited by 361
Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules.
Trinczek, B., Biernat, J., Baumann, K., Mandelkow, E. M., & Mandelkow, E. (1995) · Molecular Biology of the Cell · doi:10.1091/mbc.6.12.1887 · Cited by 340 · cited 4×
“acids each) encoded by exons 9-12 (15, 17, 18).”
BackgroundInfluentialUbiquitin is conjugated with amino-terminally processed tau in paired helical filaments
Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Titani, K., & Ihara, Y. (1993) · Neuron · doi:10.1016/0896-6273(93)90063-w · Cited by 332 · cited 2×
“The accumulation of ubiquitylated of tau appears to be a late event in the development of neurofibrillary pathology, as it occurs after the formation of NFTs (247, 248).”
BackgroundProteasomal degradation of tau protein
David, D. C., Layfield, R., Serpell, L., Narain, Y., Goedert, M., & Spillantini, M. G. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01137.x · Cited by 327 · cited 3×
“Although, in vitro, tau has been reported to be a substrate for a number of proteases such as trypsin, chymotrypsin, cathepsin D, calpains, caspases, proteasomal proteases, double-stranded DNA-stimulated protease, and thrombin (205-211), the proteases that degrade tau in brain”
BackgroundAn, W.-L., Cowburn, R. F., Li, L., Braak, H., Alafuzoff, I., Iqbal, K., Iqbal, I.-G., Winblad, B., & Pei, J.-J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63687-5 · Cited by 312
Andreadis, A. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.010 · Cited by 311
Tau domains, phosphorylation, and interactions with microtubules
Mandelkow, E.-M., Biernat, J., Drewes, G., Gustke, N., Trinczek, B., & Mandelkow, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00025-a · Cited by 308
Overexpression of tau in a nonneuronal cell induces long cellular processes.
Knops, J., Kosik, K. S., Lee, G., Pardee, J. D., Cohen-Gould, L., & McConlogue, L. (1991) · The Journal of cell biology · doi:10.1083/jcb.114.4.725 · Cited by 286
Cho, J., & Johnson, G. V. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02155.x · Cited by 282 · cited 1×
“736 in the cell as indicated by a reduction in the levels of acetylated tubulin, a marker of microtubule stability (66).”
BackgroundPP2A mRNA Expression Is Quantitatively Decreased in Alzheimer's Disease Hippocampus
Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7630 · Cited by 281 · cited 1×
“In addition, it has been reported that the expression and activities of some phosphatases are decreased in the affected area of AD brain (166-171).”
BackgroundPanda, D., Samuel, J. C., Massie, M., Feinstein, S. C., & Wilson, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633508100 · Cited by 280
Protein Kinase MARK/PAR-1 Is Required for Neurite Outgrowth and Establishment of Neuronal Polarity
Biernat, J., Wu, Y.-Z., Timm, T., Zheng-Fischhöfer, Q., Mandelkow, E., Meijer, L., & Mandelkow, E.-M. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.02-03-0046 · Cited by 279
Glycogen Synthase Kinase 3β Phosphorylates Tau at Both Primed and Unprimed Sites
Cho, J.-H., & Johnson, G. V. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206236200 · Cited by 266 · cited 4×
“By contrast, phosphorylation of tau at Ser396 and/or Ser404 did not significantly affect the ability of tau to bind microtubules (64).”
BackgroundInfluentialPark, S.-Y., & Ferreira, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1125-05.2005 · Cited by 262
Single-molecule investigation of the interference between kinesin, tau and MAP2c
Seitz, A., Kojima, H., Oiwa, K., Mandelkow, E.-M., Song, Y.-H., & Mandelkow, E. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf503 · Cited by 257 · cited 1×
“Tau has no effect on the speed or run length of kinesin once it is attached to the microtubules (97).”
BackgroundKlein, C., Krämer, E.-M., Cardine, A.-M., Schraven, B., Brandt, R., & Trotter, J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-03-00698.2002 · Cited by 250
MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons
Mandelkow, E.-M., Thies, E., Trinczek, B., Biernat, J., & Mandelkow, E. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200401085 · Cited by 236
Williamson, R., Scales, T., Clark, B. R., Gibb, G., Reynolds, C. H., Kellie, S., Bird, I. N., Varndell, I. M., Sheppard, P. W., Everall, I., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00010.2002 · Cited by 227 · cited 1×
“Tyrosine phosphorylated tau has also been reported in human fetal brain (106).”
BackgroundPei, J.-J., Grundke-Iqbal, I., Iqbal, K., Bogdanovic, N., Winblad, B., & Cowburn, R. F. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00296-0 · Cited by 226 · cited 1×
“Immunohistochemical studies have shown increased expression of several kinases, including Ca/calmodulindependent kinase, GSK3, PKA, Cdk-5, MAPK/ERK, SAPK/JNK, and casein kinase I, and co-localization with hyperphosphorylated tau deposits and NFTs in neurons in AD (58-62, 165).”
BackgroundPhosphorylation by cAMP-dependent protein kinase inhibits the degradation of tau by calpain.
Litersky, J. M., & Johnson, G. V. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45982-0 · Cited by 201 · cited 1×
“Phosphorylation of tau by PKA attenuates calpainmediated proteolysis of tau in vitro (240), and there is evidence that this the case in situ (147).”
BackgroundLovestone, S., Hartley, C. L., Pearce, J., & Anderton, B. H. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00126-1 · Cited by 201
Hirokawa, N., Funakoshi, T., Sato-Harada, R., & Kanai, Y. (1996) · The Journal of cell biology · doi:10.1083/jcb.132.4.667 · Cited by 179 · cited 1×
“strongly promotes neurite outgrowth during differentiation (7, 75-77), and even in nonneuronal cells tau induces cell processes with a cytoskeletal organization reminiscent of neurites (56, 78-80).”
BackgroundTau protein and neurodegeneration
Goedert, M. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2003.12.015 · Cited by 177
Biernat, J., & Mandelkow, E.-M. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.3.727 · Cited by 149
Inhibition of Tau Polymerization by Its Carboxy-Terminal Caspase Cleavage Fragment
Berry, R. W., Abraha, A., Lagalwar, S., LaPointe, N., Gamblin, T. C., Cryns, V. L., & Binder, L. I. (2003) · Biochemistry · doi:10.1021/bi027348m · Cited by 141
Eidenmüller, J., Fath, T., Hellwig, A., Reed, J., Sontag, E., & Brandt, R. (2000) · Biochemistry · doi:10.1021/bi001290z · Cited by 117 · cited 1×
“Recently, it has been demonstrated that pseudophosphorylation (in which a Ser/Thr is mutated to an Asp or Glu to mimic phosphorylation (49, 50)) in the Nterminal portion of tau up to amino acid 208 mainly suppressed tau aggregation, whereas mutations in the Cterminal region mainly lead to enhanced aggregation (51).”
BackgroundPseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation
Rankin, C. A., Sun, Q., & Gamblin, T. C. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.04.012 · Cited by 95 · cited 1×
“Recently, it has been also reported that pseudophosphorylation of tau at Ser205, Thr205, and Thr212 enhances polymerization of tau into filaments (50, 179).”
BackgroundIseki, E., Matsumura, T., Marui, W., Hino, H., Odawara, T., Sugiyama, N., Suzuki, K., Sawada, H., Arai, T., & Kosaka, K. (2001) · Acta Neuropathologica · doi:10.1007/s004010000333 · Cited by 93
Functional effects of tau gene mutations ΔN296 and N296H
Yoshida, H., Crowther, R. A., & Goedert, M. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00729.x · Cited by 56
Cited by
Recent aspects of the effects of zinc on human health
Chasapis, C. T., Ntoupa, P.-S. A., Spiliopoulou, C. A., & Stefanidou, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02702-9 · Cited by 702
How does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492
The importance of tau phosphorylation for neurodegenerative diseases
Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00083 · Cited by 475
“Phosphorylation of tau by GSK-3 promotes the formation of insoluble oligomeric tau species that can constitute both full-length and truncated tau species (62, 63).”
BackgroundStructure and Pathology of Tau Protein in Alzheimer Disease
Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J., & Ripova, D. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/731526 · Cited by 468
Ghosh, S., Wu, M. D., Shaftel, S. S., Kyrkanides, S., LaFerla, F. M., Olschowka, J. A., & O'Banion, M. K. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4361-12.2013 · Cited by 390
“Both GSK3 and p38MAPK have been studied for their ability to phosphorylate tau ( Chun and Johnson , 2007 ) .”
Background
Metadata
- Authors
- Chun, W.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2007
- Volume
- 12
- Issue
- 1
- Pages
- 733
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/2097
- OpenAlex
- W2050562362
- Cited by
- 142
- References
- 73
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.